Rationale Alcohol use disorders have become one of the most ethanol intake and preference in C57BL/6J mice treated with damaging psychiatric disorders in the world; however, there roflumilast (1, 3, or 10 mg/kg) or rolipram (0.5 mg/kg; posi- are no ideal treatments in clinic. Phosphodiesterase-4 (PDE4), tive control). The effect of roflumilast was verified using the an enzyme that specifically hydrolyzes intracellular cyclic ethanol drinking-in-dark (DID) test. Locomotor activity was AMP (cAMP), has been involved in alcohol use disorders. examined using the open-field test. Intake of sucrose or qui- Roflumilast is the first PDE4 inhibitor approved for treatment nine was also tested to determine whether natural reward pref- of chronic obstructive pulmonary diseases in clinic. It was of erence and aversive stimuli were involved in the effect of particular interest to researchers to determine whether PDE4 inhibitors. roflumilast altered ethanol consumption. Results Similar to rolipram, roflumilast decreased ethanol in- Objectives The present study tried to determine the effects of take and preference in two-bottle choice and DID tests in a roflumilast on ethanol intake and preference. dose-dependent manner, with significant changes at the dose of 10 mg/kg; in contrast, roflumilast did not affect sucrose or quinine drinking, although it
Psychopharmacology – Springer Journals
Published: May 6, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera